MedTrace Logo

Imaging Studies of Kidney Cancer Using 18F-VM4-037

NCT01712685 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-01-11

Study results available
· View outcomes & findings →

Summary

Background:

\- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans. Researchers want to see how well it works for scans for people who have kidney cancer.

Objectives:

\- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney cancer.

Eligibility:

\- Adults at least 18 years of age with kidney cancer that will be treated with surgery.

Design:

* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
* Participants will have two positron emission tomography (PET) scans of their kidneys. They will have the scans before and after receiving an injection of 18F-VM4-037. The scans will take about 2 hours to complete.
* About 3 weeks after the PET scans, participants will provide tumor tissue samples from their kidneys.
* This is a scanning study only. Treatment will not be provided as part of this study.

Conditions

  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Interventions

DRUG

18F-VM4-037

Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.

PROCEDURE

PET/CT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Adam R Metwalli, M.D. · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712685 on ClinicalTrials.gov